Trial Profile
Ranibizumab in Idiopathic Macular Telangiectasia, Type 2. A Prospective Interventional Non-randomized Study Comparing the Efficacy and Safety of Intravitreal Ranibizumab in Type 2 Idiopathic Macular Telangiectasia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Feb 2021
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Retinal telangiectasis
- Focus Therapeutic Use
- Acronyms RAMA
- 15 Aug 2014 New trial record
- 21 Sep 2009
- 16 Jul 2009